Valeant Pharmaceuticals International Stock Hits New 52-Week High (VRX)

NEW YORK ( TheStreet) -- Valeant Pharmaceuticals International (NYSE: VRX) hit a new 52-week high Thursday as it is currently trading at $58.51, above its previous 52-week high of $57.24 with 532,302 shares traded as of 9:35 a.m. ET. Average volume has been 1.4 million shares over the past 30 days.

Valeant Pharmaceuticals International has a market cap of $17.19 billion and is part of the health care sector and drugs industry. Shares are up 20.9% year to date as of the close of trading on Wednesday.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. The company has a P/E ratio of 114.9, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Valeant Pharmaceuticals International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, good cash flow from operations, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated. You can view the full Valeant Pharmaceuticals International Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

ADP Is Morphing Into the IBM Blob: Bill Ackman

Follow the Crucial '$20 Level Rule' When Trading Stocks

$20 Should Be Your Cutoff Point

Short the Stocks That Fall Below $20

One of the Most Recognized Hedge Fund Managers Has Had a Terrible Year